Radiopharm Theranostics files AGM 6-K

Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish investors with information already published on the Australian Securities Exchange.

Rhea-AI Filing Summary

Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish investors with information already published on the Australian Securities Exchange. The filing attaches two November 20, 2025 ASX announcements titled “Presentation to Annual General Meeting” and “Results of Meeting” as Exhibits 99.1 and 99.2.

The company notes that this Form 6-K, including its exhibits, is being furnished rather than filed under U.S. securities laws and will not be automatically incorporated into other U.S. securities filings unless specifically referenced. The report is signed on behalf of the company by Company Secretary Phillip Hains.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Radiopharm Theranostics Limited (RADX) report in this Form 6-K?

Radiopharm Theranostics Limited uses this Form 6-K to furnish two announcements it made to the Australian Securities Exchange on November 20, 2025. These announcements relate to its annual general meeting presentation and the results of that meeting, attached as Exhibits 99.1 and 99.2.

Which ASX announcements are attached to the Radiopharm Theranostics (RADX) Form 6-K?

The Form 6-K attaches two ASX announcements titled “Presentation to Annual General Meeting” and “Results of Meeting.” They are provided as Exhibit 99.1 and Exhibit 99.2, allowing U.S. investors to access the same AGM-related information disclosed on the Australian Securities Exchange.

Are the Radiopharm Theranostics (RADX) AGM materials considered "filed" under U.S. securities law?

The AGM materials are described as being furnished, not filed, under U.S. securities law. The Form 6-K states they will not be deemed filed or automatically incorporated into other U.S. securities filings unless there is a specific, express reference including them in another document.

Who signed the Radiopharm Theranostics (RADX) Form 6-K and when?

The Form 6-K was signed on behalf of Radiopharm Theranostics Limited by Company Secretary Phillip Hains. The signature block is dated November 20, 2025, aligning with the date of the attached Australian Securities Exchange announcements about the company’s annual general meeting.

What exhibits are listed in the Radiopharm Theranostics (RADX) Form 6-K?

The filing lists two exhibits: Exhibit 99.1, titled “Presentation to Annual General Meeting,” and Exhibit 99.2, titled “Results of Meeting.” These exhibits reproduce the announcements Radiopharm Theranostics Limited released to the Australian Securities Exchange on November 20, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/20/2025 - 06:18 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on November 20, 2025 titled:

“Presentation to Annual General Meeting”

“Results of Meeting”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Presentation to Annual General Meeting
99.2		Results of Meeting

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: November 20, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3